72.11.Z - Research and experimental development on biotechnology
20.14.Z - Manufacture of other organic basic chemicals
21.10 - Manufacture of basic pharmaceutical substances
21.20 - Manufacture of medicines and other pharmaceutical products
58.29.Z - Other software publishing
63.11.Z - Data processing, hosting and related activities
63.12.Z - Web portals
63.99.Z - Other information service activities not elsewhere classified
66.19.Z - Other activities auxiliary to financial services, except insurance and pension funding
72.19.Z - Other research and experimental development on natural sciences and engineering
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | -4,5 | -21,7 | -33,5 | -54,1 |
EBITDA | -4,5 | -21,2 | -33,4 | -57,4 |
Short time liabilities | 2,6 | 24,2 | 20,5 | -15,3 |
Equity capital | 0,5 | -21,2 | -54,7 | -158 |
Operating profit (EBIT) | -4,5 | -21,2 | -33,4 | -57,4 |
Assets | 103 | 70,2 | 33 | -52,9 |
Net profit (loss) | -4,5 | -21,7 | -33,5 | -54,1 |
Cash | 90,4 | 53,1 | 16,4 | -69,2 |
Net income from sale | 0 | 0 | 14 | -∞ |
Liabilities and provisions for liabilities | 102,5 | 91,4 | 87,7 | -4 |
Working assets | 102,3 | 69,4 | 32,3 | -53,5 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -830 | 102,5 | 61,2 | -41,3 |
Equity capital to total assets | 0,5 | -30,2 | -165,5 | -135,3 |
Gross profit margin | -239,1 | |||
EBITDA Margin | -238,9 | |||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 534 | -2 147 483 114 |
Current financial liquidity indicator | 0.9979277849197388 | 0.7599680423736572 | 0.3681354224681854 | -0,4 |
Net dept to EBITDA | 20.26924705505371 | 2.498077392578125 | 0.48907262086868286 | -2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane